Crinetics Pharmaceuticals Inc (CRNX) Stock Price, Quote & News

Company Profile

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant,...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 450 6464

Website: www.crinetics.com

Address:

6055 Lusk Boulevard, San Diego, United States

SuperGreenToday Feb. 2 at 3:08 PM

$CRNX Share Price: $50.27 Contract Selected: Sep 18, 2026 $50 Calls Buy Zone: $6.21 – $7.67 Target Zone: $10.38 – $12.69 Potential Upside: 58% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

SuperGreenToday Jan. 30 at 2:41 PM

$CRNX Share Price: $52.44 Contract Selected: Sep 18, 2026 $50 Calls Buy Zone: $10.48 – $12.95 Target Zone: $17.35 – $21.21 Potential Upside: 56% ROI Time to Expiration: 230 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

ClinicalTrialsDaily Jan. 27 at 1:20 PM

$CRNX $NBIX Consolidated View: Market is big enough for both. $NBIX = Standard of Care for the masses. $CRNX = The 'Heavy Lift' for severe cases & TARTs. Watch for 'Clinical Superiority' designation for $CRNX to bypass orphan exclusivity. That is the key regulatory unlock. Read more: www.clinicaltrialsdaily.com/mc2r-antagonism-refractory-cah-potency/

1 · Reply

BioTechHealthX Jan. 25 at 4:46 PM

$CRNX Not every biotech needs fireworks on day one. Crinetics Pharmaceuticals (NASDAQ:CRNX) is building steady value in endocrine diseases—and CRNX stock reflects that patience. https://biotechhealthx.com/biotech-news/why-crinetics-pharmaceuticals-crnx-is-the-slow-burn-biotech-investors-love/

0 · Reply

TipRanks Jan. 16 at 11:10 AM

‘Markets Climb Wall-of-Worry’: Oppenheimer Sees Resilience Driving 2026 and Suggests 2 Stocks to Buy https://www.tipranks.com/news/article/markets-climb-wall-of-worry-oppenheimer-sees-resilience-driving-2026-and-suggests-2-stocks-to-buy $AMPX $CRNX

1 · Reply

BillionerOfKing Jan. 15 at 11:07 AM

$CRNX Current Stock Price: $55.48 Contracts to trade: $55 CRNX Jan 16 2026 Call Entry: $1.53 Exit: $2.42 ROI: 58% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

RunnerSignals Jan. 13 at 7:46 PM

$OPRT $VIST $CRNX $NFLX $RDDT Analyst upgrades are flying! Which stock could blast off first? Traders are buzzing, don't miss the action! https://stocksrunner.com/news/2026-01-13-stock-upgrades-today-reveal-top-buy

0 · Reply

erevnon Jan. 12 at 6:31 PM

Goldman Sachs upgrades Crinetics Pharmaceuticals $CRNX from Neutral to Buy and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

notreload_ai Jan. 12 at 12:41 PM

Goldman Sachs and JPMorgan highlight new clinical data that strengthen the outlook for $CRNX and $FULC , citing clearer paths to success and upside potential. https://notreload.xyz/goldman-jpmorgan-turn-bullish-on-crnx-and-fulc/

0 · Reply

GettnFibbywIT Jan. 11 at 8:31 AM

$CRNX $QQQ

0 · Reply

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Jan 22, 2026, 4:05 PM EST - 12 days ago

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Jan 13, 2026, 3:56 PM EST - 21 days ago

Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 4:05 PM EST - 22 days ago

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2026, 9:22 PM EST - 4 weeks ago

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Jan 5, 2026, 4:02 PM EST - 4 weeks ago

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Jan 5, 2026, 1:27 PM EST - 4 weeks ago

Crinetics Pharmaceuticals, Inc. (CRNX) Discusses PALSONIFY Launch Progress and Phase 2 Atumelnant Results in Congenital Adrenal Hyperplasia Transcript

Jan 5, 2026, 8:00 AM EST - 4 weeks ago

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

Jan 4, 2026, 4:00 PM EST - 4 weeks ago

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

Dec 18, 2025, 4:05 PM EST - 6 weeks ago

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 4:05 PM EST - 7 weeks ago

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Dec 10, 2025, 4:34 PM EST - 7 weeks ago

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 3, 2025, 8:00 AM EST - 2 months ago

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

Nov 20, 2025, 4:05 PM EST - 2 months ago

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

Nov 10, 2025, 4:28 PM EST - 3 months ago

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2025, 12:46 PM EST - 3 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 3 months ago

Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 23, 2025, 8:00 AM EDT - 3 months ago

Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting

Oct 10, 2025, 4:41 PM EDT - 4 months ago

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 6, 2025, 4:05 PM EDT - 4 months ago

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 26, 2025, 5:00 PM EDT - 4 months ago

Crinetics: FDA Approval And Expansion Of Palsonify In Focus, Maintaining 'Buy' Rating

Sep 26, 2025, 1:57 AM EDT - 4 months ago

Crinetics Pharmaceuticals, Inc. - Special Call

Sep 25, 2025, 5:30 PM EDT - 4 months ago

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

Sep 10, 2025, 4:30 PM EDT - 5 months ago

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 21, 2025, 8:45 AM EDT - 5 months ago

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

Aug 11, 2025, 4:05 PM EDT - 6 months ago

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 9, 2025, 11:21 AM EDT - 6 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 6 months ago

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 13, 2025, 5:45 PM EDT - 7 months ago

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

Jul 11, 2025, 8:00 AM EDT - 7 months ago

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 10, 2025, 4:28 PM EDT - 7 months ago

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2025, 4:05 PM EDT - 7 months ago

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline

Jun 16, 2025, 8:00 AM EDT - 8 months ago

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

Jun 10, 2025, 4:29 PM EDT - 8 months ago

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 23, 2025, 8:00 AM EDT - 9 months ago

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

May 15, 2025, 4:05 PM EDT - 9 months ago

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

May 12, 2025, 4:05 PM EDT - 9 months ago

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 10, 2025, 1:50 PM EDT - 9 months ago

Crinetics Pharmaceuticals, Inc (CRNX) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 9 months ago

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 11, 2025, 8:00 AM EDT - 10 months ago

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 10, 2025, 5:04 PM EDT - 10 months ago

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 2, 2025, 2:15 PM EDT - 10 months ago

Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA

Mar 27, 2025, 4:05 PM EDT - 11 months ago

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

Mar 10, 2025, 4:36 PM EDT - 11 months ago

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 28, 2025, 1:01 PM EST - 1 year ago

Crinetics Pharmaceuticals, Inc (CRNX) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 1 year ago

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 24, 2025, 8:30 AM EST - 1 year ago

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

Feb 20, 2025, 4:05 PM EST - 1 year ago

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

Feb 10, 2025, 4:44 PM EST - 1 year ago

Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 6, 2025, 4:35 PM EST - 1 year ago

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

SuperGreenToday Feb. 2 at 3:08 PM

0 · Reply

SuperGreenToday Jan. 30 at 2:41 PM

0 · Reply

ClinicalTrialsDaily Jan. 27 at 1:20 PM

1 · Reply

BioTechHealthX Jan. 25 at 4:46 PM

0 · Reply

TipRanks Jan. 16 at 11:10 AM

1 · Reply

BillionerOfKing Jan. 15 at 11:07 AM

0 · Reply

RunnerSignals Jan. 13 at 7:46 PM

0 · Reply

erevnon Jan. 12 at 6:31 PM

Goldman Sachs upgrades Crinetics Pharmaceuticals $CRNX from Neutral to Buy and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

notreload_ai Jan. 12 at 12:41 PM

0 · Reply

GettnFibbywIT Jan. 11 at 8:31 AM

$CRNX $QQQ

0 · Reply

IN0V8 Jan. 8 at 4:48 PM

$CRNX Buy Leerink Partners raises PT to $92 from $88

0 · Reply

Spicy_Trade Jan. 8 at 5:38 AM

Crinetics Pharmaceuticals, Inc. ( $CRNX ) daily stock analysis by SpicyT... https://youtu.be/tSNWka4Nsao?si=oeH41o0coxqTc-97

0 · Reply

Bogy99 Jan. 7 at 10:25 PM

$ARWR $CRNX is a good example of what you should expect tomorrow with this. Both companies did the ole price the next day garbage. You have the demand, price it that night. Hopefully nobody sold today. Upwards and onwards.

0 · Reply

Bondra Jan. 7 at 4:23 PM

$CRNX Easiest re-enter i EVER saw yesterday

0 · Reply

Rascal7777777 Jan. 7 at 3:47 PM

$CRNX is this a buyout candidate?

3 · Reply

Walleyeslayer Jan. 7 at 3:14 PM

$CRNX Well sometimes I impress myself! What a run in just 2 days.

0 · Reply

CDMO Jan. 7 at 2:32 PM

$CRNX easy money

0 · Reply

OpenOutcrier Jan. 7 at 1:59 PM

$CRNX (+8.8% pre) Crinetics prices $350 million stock offering at $45.95 per share https://ooc.bz/l/88887

1 · Reply

Walleyeslayer Jan. 7 at 12:55 AM

$CRNX A company with a large pipeline and money 💴 n the bank. I’m in. 🤫

0 · Reply

Hanaleimike Jan. 6 at 7:13 PM

$CRNX someone correct me if I’m wrong but it looks like they ran up the price with an announcement only to then make an offering and dilute retail further? I’d like to be part of that team please, maybe send me a memo next time?

2 · Reply

Bogy99 Jan. 6 at 5:24 PM

$CRNX whoever handled this offering should be fired. Really not that hard to do especially if there is demand.

3 · Reply

Arcides Jan. 6 at 4:10 PM

$CRNX

0 · Reply

Market Cap	4.74B
Revenue (ttm)	1.04M
Net Income (ttm)	-298.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-28,693.27%
Debt to Equity Ratio	0.00

Volume	828,300
Avg Vol	1,228,738
Day's Range	N/A - N/A
Shares Out	94.89M
Stochastic %K	17%
Beta	0.20
Analysts	Strong Sell
Price Target	$84.15